WeDaita BioMedAI · Agentic AI

From Target to Candidate —
in One Platform

Agentic AI for Target Discovery and Therapeutic Design. Autonomous AI agents and proprietary models turn one research question into ranked targets and optimized drug candidates — cutting months of manual triage down to days. Combine public data with your own private data to surface deeper insight and decide with confidence.

Try BioMedAI Full AI platform Book a Call 30-min consultation
  See It in Action
300+MCP Tools
40+Databases
GraphRAGReasoning
Proprietary AI Models
CLINAVA clinical progression
GENAVA virtual target validation
Long-term vision

Bring Better Medicine to Patients Faster with AI

Human gate
1

AI Target Discovery

Target Intelligence

  • Analyze public + proprietary data
  • Predict disease-driving targets
  • Deliver a ranked target list
OutputRanked drug targetsFrom disease to the right targets
Human gate
2

AI Drug Design

Modality-optimized candidates

  • Small molecules, antibodies, peptides
  • Generate & optimize per target
  • Improve efficacy, safety, developability
OutputOptimized drug candidatesFor each target, across modalities
3

Lab & Clinical Validation

Delivered through partners

  • Drug safety & toxicity assessment
  • Pharmacokinetics / pharmacodynamics (PK/PD)
  • Clinical evidence & validation
OutputLab-validated leadsReady for further development
Experimental results can sharpen your own target and candidate selection  ·  Human gates: scientists review and approve every handoff
Bringing medicine to patients earlier isn’t just about saving time and money — it’s about saving lives.
Proprietary AI models

Decisions you can trace and trust

Clinical progression

CLINAVA™

Predicts how far a target is likely to progress clinically, giving a quantitative basis for choosing which targets to pursue.

Virtual cell

GENAVA™

Simulates gene perturbations in silico to validate a target and trace the biological pathways behind each recommendation.

Validate Drug Targets with AI Precision

See how BioMedAI analyzes biomedical data to identify and validate potential drug targets

  • Integrated analysis from 40+ biomedical databases
  • AI-powered target validation and scoring
  • Comprehensive pathway and interaction insights
  • Evidence-based target recommendations
AI RESEARCH INTELLIGENCE

Research Digest

AI-curated papers, FDA approvals, clinical compounds, and disclosures from drug discovery's leading sources — scored for relevance by the WeDaita AI agent every week.

Explore Research Digest
Target Identification
GWAS associations, CRISPR screen hits, druggability assessments
Peer-reviewed evidence and industry pipeline news on novel drug targets, scored for translational relevance.
Drug Design
FDA approvals, clinical compounds, molecular disclosures, patents
AI molecular generation, openFDA NDA approvals, ChEMBL Phase I–III candidates, and Drug Hunter patent roundups.
Clinical Trials
Active trials, regulatory milestones, trial methodology
ClinicalTrials.gov updates, FDA and EMA designations, IND filings, and patient stratification research.
3Topics
WeeklyUpdates
WeDaita AIRelevance Scoring
6+Data Sources
Latest from WeDaita

News & Blog

Company updates, tutorials, and community posts — all in one place.

Stay Ahead

AI Drug Discovery, Delivered Monthly

Get curated insights on AI-driven target identification, therapeutic design, and BioMedAI platform updates — directly to your inbox.

No spam. Unsubscribe at any time. We respect your privacy.

The Team

Built by People Who Have Lived the Problem

Combining deep domain expertise across AI, biology and chemistry in both academia and industry.

Wenliang Zhang
Wenliang Zhang, PhD, MMed
Founder, CEO/CTO
  • Director of Data Science: Pfizer, Exo Therapeutics
  • Principal Data Engineer: AbbVie
  • Principal Software Engineer: PerkinElmer, Akoya Bio
  • Computational Biologist: Bluebird Bio, Tesaro
Chao Yang
Chao Yang, PhD
AI/ML Computational Chemistry Advisor
  • PhD in Chemistry, New York University
  • Postdoc Research, The Rockefeller University
  • Computational Chemistry: Axle Informatics, Exo Therapeutics
  • AI-guided Virtual Screening and Drug Design
Elena Chernokalskaya
Elena Chernokalskaya, Ph.D
Mentor and Growth Advisor
  • Founder, Boston Business Mentor
  • Certified Counselor, SCORE Mentors
  • Scientific Advisory Board, 908 Devices
  • Executive, Cytiva & GE Helathcare
  • Proteomics Group Leader, Vertex Pharmaceuticals
All Members  
The validation

Early Traction & Momentum

Early signals of market curiosity and institutional engagement across the scientific community.

120+
Early users

Individual users across biotech, pharma and research institutions

70+
Organizations

Institutional organizations with active test users on the platform

Role distribution

  • Researcher / Scientist22%
  • Other15%
  • Drug Discovery Scientist10%
  • Student10%
  • Biotech Founder / Executive7%
  • Clinician2%
  • Not specified34%
The Validation

Ecosystem Recognition & Strategic Support

Selected by leading innovation programs supporting AI and life sciences.

NVIDIA Inception Program

Member of NVIDIA’s global startup program accelerating AI innovation — providing access to the NVIDIA AI ecosystem, technical resources, and industry connections.

awsActivate

Qualified for AWS startup support, cloud credits, and infrastructure resources to accelerate scalable AI platform development.

Harvard Business School Foundry

Selected for entrepreneurial support and founder ecosystem access through Harvard Business School’s innovation programs.

Ready to Accelerate Your Drug Discovery?

BioMedAI is live — start with AI Target Discovery and antibody & protein design today.

  Try BioMedAI   Book a Demo